Doc,
I frankly doubt if many companies have any idea whether the therapeutics they market could have synergies that work with DCVax-L or Direct which in fact could increase sales, rather than reducing them. Sure, Merck feels strong about Keytruda, but how many others may also work as our vaccines open the door to treatment by others. We need to remember that the longer patients survive the more they'll use for their healthcare, use of some products may be curtailed, but other products will be enhanced.
I frankly have no idea if the vaccine itself can be modified to add drugs like Keytruda, that seems to be the directions some believe it could take. As I see it, many different products may work with our vaccines, and very probably different products will do better in different forms of cancer. The only way to really know is with clinical trials, I suspect that once our vaccine has been approved many companies could get in line to try their products with our vaccine in new clinical trials. I don't know, but I wouldn't be surprised if NWBO could be nicely paid for the vaccine used in trials in combination with others therapeutics.
Once approved, I don't believe that NWBO can dictate what other therapeutics can and can't be utilized with it in spite of the combination never previously being tested. Off label Drs. will be able to try what they wish, just as they will be able to try DCVax's in cancer forms that haven't been previously tried. I frankly can't say how far insurance companies will be willing to go, but I tend to believe that if my Dr. at City of Hope fought to use a product the insurance company would allow it. I rarely was delayed for over a few days in getting products he wanted me to have.
Gary
Market Data 
Markets 
AI
